Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 4/20 | 0.55 |
| ▸ | MERTK | Q12866 | 1/20 | 0.48 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | MAX | P61244 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12374079 | 0.82 | PIN1 (0.57) | PIN1MERTKKMT2AMEN1THRB | |
| SCHEMBL30068176 | 0.80 | MYC (0.53) | MERTKMYCMAXAPPTDP1 | |
| SCHEMBL4651273 | 0.80 | MYC (0.53) | MERTKMYCMAXAPPTDP1 | |
| SCHEMBL4652574 | 0.79 | APP (0.67) | PIN1MYCMAXMCL1APP | |
| SCHEMBL12374077 | 0.79 | PIN1 (0.57) | PIN1MERTKKMT2AMEN1THRB | |
| SCHEMBL21515183 | 0.78 | KMT2A (0.47) | PIN1MERTKMYCMAXAPP | |
| SCHEMBL4652365 | 0.77 | MYC (0.56) | MYCMAXMCL1APPTDP1 | |
| SCHEMBL31326400 | 0.77 | MYC (0.50) | MERTKMYCMAXAPPTDP1 | |
| SCHEMBL23005125 | 0.76 | FPR2 (0.53) | PIN1MYCMAXAPP | |
| SCHEMBL23005126 | 0.76 | FPR2 (0.53) | PIN1MYCMAXAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12357634-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2025-07-15 | — | — | US | disclosed |
| CN-112218858-B | 2, 6-Diamino-3, 4-dihydropyrimidin-4-one derivatives and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2024-06-18 | — | — | CN | disclosed |
| EP-3781554-B1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2023-06-28 | — | — | EP | disclosed |
| US-20230110478-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2023-04-13 | — | — | US | disclosed |
| US-11504368-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2022-11-22 | — | — | US | disclosed |
| US-20210052587-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | MEDICINSK FORSKNING (SE) | 2021-02-25 | — | — | US | disclosed |
| EP-3781554-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | Thomas Helledays stiftelse för medicinsk forskning (SE) | 2021-02-24 | — | — | EP | disclosed |
| CN-112218858-A | 2, 6-diamino-3, 4-dihydropyrimidin-4-one derivatives and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2021-01-12 | — | — | CN | disclosed |
| WO-2019201991-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11504368-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | IL2, THPO, IL6 | PIN1 980/4885MERTK 1464/4885MYC 2431/4885 |
| US-20230110478-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | IL2, THPO, IL6 | PIN1 927/4885MERTK 1400/4885MYC 2305/4885 |
| US-12357634-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | IL2, THPO, IL6 | PIN1 927/4885MERTK 1400/4885MYC 2305/4885 |
| US-20210052587-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | IL2, THPO, IL6 | PIN1 980/4885MERTK 1464/4885MYC 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.